James Ford

1.3k total citations · 1 hit paper
7 papers, 617 citations indexed

About

James Ford is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, James Ford has authored 7 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 3 papers in Organic Chemistry and 2 papers in Oncology. Recurrent topics in James Ford's work include Melanoma and MAPK Pathways (4 papers), Click Chemistry and Applications (3 papers) and Protein Degradation and Inhibitors (3 papers). James Ford is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Click Chemistry and Applications (3 papers) and Protein Degradation and Inhibitors (3 papers). James Ford collaborates with scholars based in United States, Germany and Italy. James Ford's co-authors include Helene Cauwel, Joyce Y. Wu, Е. Д. Белоусова, Rachel Kuperman, David Lebwohl, Vicky Whittemore, Olaf Witt, Steven Sparagana, Sergiusz Jóźwiak and Paolo Curatolo and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

James Ford

7 papers receiving 611 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

2012 578 citations David Neal Franz, Е. Д. Белоусова et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Ford United States	4	385	206	203	119	74	7	617
Helene Cauwel United States	3	385 1.0×	180 0.9×	183 0.9×	122 1.0×	79 1.1×	4	600
Andrés Nieto Spain	7	689 1.8×	379 1.8×	260 1.3×	122 1.0×	38 0.5×	8	981
Izabela A. Malinowska United States	11	404 1.0×	289 1.4×	258 1.3×	220 1.8×	18 0.2×	30	690
Yvonne Chekaluk United States	9	417 1.1×	288 1.4×	181 0.9×	143 1.2×	22 0.3×	11	680
Jolanta Kasprzyk‐Obara Poland	7	879 2.3×	292 1.4×	346 1.7×	152 1.3×	45 0.6×	11	1.0k
Piero Pignataro Italy	10	99 0.3×	155 0.8×	63 0.3×	64 0.5×	137 1.9×	14	379
C. J. Vissers Netherlands	8	72 0.2×	352 1.7×	87 0.4×	177 1.5×	29 0.4×	10	585
Gary McIntosh United Kingdom	8	41 0.1×	191 0.9×	249 1.2×	77 0.6×	48 0.6×	9	491
Takakazu Yokoyama Japan	10	96 0.2×	209 1.0×	69 0.3×	52 0.4×	30 0.4×	17	466
Eleanor Latta Canada	11	71 0.2×	135 0.7×	214 1.1×	101 0.8×	14 0.2×	19	535

Countries citing papers authored by James Ford

Since Specialization

Citations

This map shows the geographic impact of James Ford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Ford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Ford more than expected).

Fields of papers citing papers by James Ford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Ford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Ford. The network helps show where James Ford may publish in the future.

Co-authorship network of co-authors of James Ford

This figure shows the co-authorship network connecting the top 25 collaborators of James Ford. A scholar is included among the top collaborators of James Ford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Ford. James Ford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Dummer, Reinhard, Dirk Schadendorf, Paolo A. Ascierto, et al.. (2016). Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.. Journal of Clinical Oncology. 34(15_suppl). 9500–9500. 24 indexed citations

2.

Long, Georgina V., Reinhard Dummer, Keith T. Flaherty, et al.. (2015). Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy. Cancer Research. 75(14_Supplement). B16–B16. 1 indexed citations

3.

Idos, Gregory, Allison W. Kurian, Kevin McDonnell, et al.. (2015). “The GI Gap” in Genetic Testing for Inherited Susceptibility to Cancer. The American Journal of Gastroenterology. 110. S606–S607. 1 indexed citations

4.

Flaherty, Keith T., Petr Arenberger, Paolo A. Ascierto, et al.. (2014). NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma.. Journal of Clinical Oncology. 32(15_suppl). TPS9102–TPS9102. 7 indexed citations

5.

Dummer, Reinhard, Petr Arenberger, Paolo A. Ascierto, et al.. (2014). Nemo: a Phase 3 Trial of Binimetinib (Mek162) Versus Dacarbazine in Patients with Advanced Nras-Mutant Melanoma Who are Untreated or Have Progressed After Any Number of Immunotherapy Regimens. Annals of Oncology. 25. iv392–iv392. 4 indexed citations

6.

Franz, David Neal, Е. Д. Белоусова, Steven Sparagana, et al.. (2012). Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. 381(9861). 125–132. 578 indexed citations breakdown →

7.

Franz, David Neal, Christopher Kingswood, Sergiusz Jóźwiak, et al.. (2012). Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2.. Journal of Clinical Oncology. 30(15_suppl). 10619–10619. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact